Soo-Ok Kim1, Young-Mi Ah2, Yun Mi Yu1, Kyung Hee Choi3, Wan-Gyoon Shin1, Ju-Yeun Lee4. 1. College of Pharmacy, Seoul National University, Seoul, South Korea. 2. College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, South Korea. 3. College of Pharmacy, Suncheon University, Suncheon, Joellanam-do, South Korea. 4. College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, South Korea. Electronic address: jypharm@hanyang.ac.kr.
Abstract
BACKGROUND: The effects of probiotics on the treatment of atopic dermatitis (AD) are inconclusive. OBJECTIVE: To determine the clinical effect of probiotics in the management of AD overall and in different age groups. METHODS: A comprehensive search of databases through December 2013 was performed. For this meta-analysis, randomized controlled trials measuring the treatment effects of probiotics or synbiotics in patients diagnosed with AD were included. The primary outcome was a difference in Scoring of Atopic Dermatitis (SCORAD) values between the treatment and placebo groups overall and in different age populations. RESULTS: Twenty-five randomized controlled trials (n = 1,599) were available for this meta-analysis. Significant differences in SCORAD values favoring probiotics over the control were observed overall (mean -4.51, 95% confidence interval -6.78 to -2.24), in children 1 to 18 years old (-5.74, 95% confidence interval -7.27 to -4.20), and in adults (-8.26, 95% confidence interval -13.28 to -3.25). However, the effectiveness of probiotics in infants (<1 year old) with AD was not proved. The effect of synbiotic use was not significantly different from that of probiotic use. Treatment with a mixture of different bacterial species or of Lactobacillus species showed greater benefit than did treatment with Bifidobacterium species alone. CONCLUSION: The overall result of this meta-analysis suggests that probiotics could be an option for the treatment of AD, especially for moderate to severe AD in children and adults. However, no evidence was found supporting the beneficial role of probiotics in infants.
BACKGROUND: The effects of probiotics on the treatment of atopic dermatitis (AD) are inconclusive. OBJECTIVE: To determine the clinical effect of probiotics in the management of AD overall and in different age groups. METHODS: A comprehensive search of databases through December 2013 was performed. For this meta-analysis, randomized controlled trials measuring the treatment effects of probiotics or synbiotics in patients diagnosed with AD were included. The primary outcome was a difference in Scoring of Atopic Dermatitis (SCORAD) values between the treatment and placebo groups overall and in different age populations. RESULTS: Twenty-five randomized controlled trials (n = 1,599) were available for this meta-analysis. Significant differences in SCORAD values favoring probiotics over the control were observed overall (mean -4.51, 95% confidence interval -6.78 to -2.24), in children 1 to 18 years old (-5.74, 95% confidence interval -7.27 to -4.20), and in adults (-8.26, 95% confidence interval -13.28 to -3.25). However, the effectiveness of probiotics in infants (<1 year old) with AD was not proved. The effect of synbiotic use was not significantly different from that of probiotic use. Treatment with a mixture of different bacterial species or of Lactobacillus species showed greater benefit than did treatment with Bifidobacterium species alone. CONCLUSION: The overall result of this meta-analysis suggests that probiotics could be an option for the treatment of AD, especially for moderate to severe AD in children and adults. However, no evidence was found supporting the beneficial role of probiotics in infants.
Authors: Emilia Ghelardi; Ana Teresa Abreu Y Abreu; Christian Boggio Marzet; Guillermo Álvarez Calatayud; Marcos Perez; Ana Paula Moschione Castro Journal: Microorganisms Date: 2022-06-17
Authors: Vicente Navarro-López; Ana Ramírez-Boscá; Daniel Ramón-Vidal; Beatriz Ruzafa-Costas; Salvador Genovés-Martínez; Empar Chenoll-Cuadros; Miguel Carrión-Gutiérrez; José Horga de la Parte; David Prieto-Merino; Francisco M Codoñer-Cortés Journal: JAMA Dermatol Date: 2018-01-01 Impact factor: 10.282